# A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

> **NCT02468674** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 160 (actual)

## Conditions studied

- Sarcopenia

## Interventions

- **DRUG:** bimagrumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02468674
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-22
- **Primary completion:** 2018-12-03
- **Final completion:** 2018-12-03
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02468674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02468674, "A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02468674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*